Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy

British Medical Journal

Volumn 324, Issue 7340, 2002, Pages 757-760

  Jordan, Rachel ^a   Gold, Lisa ^a   Cummins, Carole ^a   Hyde, Chris ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037196929     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Antiretroviral therapy for HW infection in 1996. Recommendations of an international panel
2. British HW Association guidelines for antiretroviral treatment of HW seropositive individuals
3. Antiretroviral therapy in adults. Updated recommendations of the International ADS Society - USA panel
4. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex
5. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness
6. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals
7. 3
8. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence
9. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials
10. Beta blockade during and after myocardial infarction: An overview of the randomized trials
11. Summing up evidence: One answer is not always enough
12. Why sources of heterogeneity in meta-analysis should be investigated
13. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
14. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
15. 3
16. Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients
17. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team
18. Functional status and wall-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection
19. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex
20. Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients
21. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial
22. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 per cubic millimeter
23. Obtaining data from randomised controlled trials: How much do we need for reliable and informative meta-analyses?
24. Clinical progression and virological failure on highly active antiretroviral therapy in H1V-1 patients: A prospective cohort study
25. AIDS across Europe, 1994-98: The EuroSIDA study
26. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV cohort study
27. Changing patterns of mortality across Europe in patients infected with H1V-1
28. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE collaboration. Concerted action on seroconversion to AIDS and death in Europe
29. Declining morbidity, and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators